Respicardia Overview

  • Founded
  • 2006
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 81
Employees
  • Latest Deal Type
  • M&A
  • Investors
  • 1

Respicardia General Information

Description

Developer of an implantable phrenic nerve stimulator technology designed to meet the needs in respiratory and cardiovascular disease with safe and effective therapies. The company's technology offers a transvenous implantable neurostimulation system that stimulates the phrenic nerve and improves respiratory rhythm management and cardiovascular health, enabling patients to restore natural breathing during sleep.

Contact Information

Website
www.respicardia.com
Formerly Known As
Cardiac Concepts
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Therapeutic Devices
Parent Company
ZOLL Medical
Primary Office
  • 12400 Whitewater Drive
  • Suite 150
  • Minnetonka, MN 55343
  • United States
+1 (952) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Respicardia Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Merger/Acquisition 09-Apr-2021 00000 Completed Generating Revenue
8. Later Stage VC (Series D) 18-Dec-2017 000.00 00000 00000 Completed Generating Revenue
7. Later Stage VC (Series D) 28-Oct-2014 000.00 000.00 00000 Completed Generating Revenue
6. Later Stage VC (Series D) 29-Aug-2013 0000 000.00 0000 Completed Generating Revenue
5. Debt - General 06-Aug-2012 000 000.00 Completed Generating Revenue
4. Later Stage VC (Series C) 11-Aug-2010 000.00 000.00 000.00 Completed Generating Revenue
3. Accelerator/Incubator 01-Jan-2010 000.00 Completed Generating Revenue
2. Later Stage VC (Series B) 17-Oct-2008 $21M $26.7M 000.00 Completed Generating Revenue
1. Early Stage VC (Series A) 08-Dec-2006 $5.64M $5.64M 000.00 Completed Startup
To view Respicardia’s complete valuation and funding history, request access »

Respicardia Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series D 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series D1 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00
Series C1 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00
Series C 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series B 15,800,000 $0.010000 $0.11 $1.33 $1.33 1x $1.33 13.78%
Series A 4,903,973 $0.010000 $0.09 $1.15 $1.15 1x $1.15 4.28%
To view Respicardia’s complete cap table history, request access »

Respicardia Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of an implantable phrenic nerve stimulator technology designed to meet the needs in respiratory and cardiovasc
Therapeutic Devices
Minnetonka, MN
81 As of 2021
00000
000000&0 00000

000000

lum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa q
00000000000 0000000
Mont-Saint-Guibert, Belgium
00 As of 0000
00000
0000 0000-00-00
00000000 00000

0000000

at. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla par
00000000000 0000000
Zhubei, Taiwan
00 As of 0000
00000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Respicardia Competitors (5)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Nyxoah Formerly VC-backed Mont-Saint-Guibert, Belgium 00 00000 00000000 00000
0000000 Formerly VC-backed Zhubei, Taiwan 00 00000000
000000 Venture Capital-Backed Arden Hills, MN 00 000.00 00000000000 000.00
0000000 0000000 00 Formerly VC-backed Maple Grove, MN 000 00000 00000000 00000
00000000 00000 000 Corporation
You’re viewing 5 of 5 competitors. Get the full list »

Respicardia Patents

  • 37

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 2

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Respicardia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2013504372-A Respiratory correction Granted 10-Sep-2009 0000000000 0
JP-5997048-B2 Respiratory correction Active 10-Sep-2009 0000000000
JP-5972318-B2 System for treating respiratory disorders Active 10-Sep-2009 0000000000
JP-2015013130-A Respiratory rectification Granted 10-Sep-2009 0000000000 0
CA-2773534-A1 Respiratory rectification Granted 10-Sep-2009 A61N1/3601
To view Respicardia’s complete patent history, request access »

Respicardia Executive Team (7)

Name Title Board Seat Contact Info
Peter Sommerness Chief Executive Officer, President and Board Member
Timothy Hauch Chief Financial Officer
Frank Piskolich JD General Counsel
Todd Goblish Vice President, Research & Development
Robin Germany MD Chief Medical Officer
You’re viewing 5 of 7 executive team members. Get the full list »

Respicardia Board Members (12)

Name Representing Role Since
Jonathan Rennert Self Board Member 000 0000
Kirk Nielsen Versant Ventures Board Member 000 0000
Scott Ward Self Board Member 000 0000
William Abraham MD Self Board Member 000 0000
You’re viewing 4 of 12 board members. Get the full list »

Respicardia Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Respicardia Former Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Abbott Ventures Corporate Venture Capital Minority 000 0000 000000 0
Accuitive Medical Ventures Venture Capital Minority 000 0000 000000 0
Affinity Capital Management Venture Capital Minority 000 0000 000000 0
Ares Capital Corporation BDC PE/Buyout Minority 000 0000 000000 0
Coridea VC-Backed Company Minority 000 0000 000000 0
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial